Annuncio • Jan 06
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment Clearmind Medicine Inc. announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent application refers to Clearmind's successful collaboration with SciSparc Ltd. ("SciSparc"), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-AcylethanOLamines family, including Palmitoylethanolamide. Annuncio • Jan 02
Clearmind Medicine Inc. Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office Clearmind Medicine Inc. announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office. The allowed patent is directed, among others to be used as primary amine aminoindan compound to regulate binge behavior. This includes primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest granted patent in Macau, a special administrative region of China, further strengthens Clearmind's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families, with patents granted in major jurisdictions such as the US, Europe, China, India, Hong Kong and now Macau. Annuncio • Dec 25
Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical Trial Clearmind Medicine Inc. announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be led at Yale School of Medicine’s Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind’s FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100. The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the advancement of CMND-100 through the clinical pipeline. Annuncio • Nov 21
Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025 Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025. Annuncio • Sep 17
Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy Clearmind Medicine Inc. announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). Annuncio • Aug 22
Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment Clearmind Medicine Inc. announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program. The approved patent claims cover, among other things, a method of regulating the consumption of alcoholic beverages and a method of controlling binge behavior through the administration of an amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest patent further bolsters Clearmind’s extensive intellectual property portfolio in the psychedelic sector, which now includes 29 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India. Annuncio • Aug 07
Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug Clearmind Medicine Inc. announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem. Key findings from the study include: Weight loss: MEAI significantly reduced diet-induced obesity in mice by decreasing fat mass while preserving lean mass. Improved Metabolism: MEAI significantly improved glycemic control by reducing hyperglycemia, glucose intolerance and hyperinsulinemia, highlighting its therapeutic potential in regulating glucose metabolism. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing fat accumulation. Increased Energy Expenditure: MEAI increased energy expenditure and fat utilization while maintaining a similar food consumption. Activity: MEAI increased activity-specific energy expenditure without overstimulation supporting its potential to impact energy balance. These findings are based on the results from Clearmind Medicine’s study aimed to investigate the ability of MEAI to modulate metabolism and counteract obesity. This comprehensive study was published in ACS Pharmacology and Translational Science. Annuncio • Jul 16
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss Clearmind Medicine Inc. announced that it has submitted an additional patent application with the United States Patent and Trademark Office ("USPTO"), as part of its ongoing collaborations with SciSparc Ltd. ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with invented with Prof. Joseph Tam from the Hebrew University's technology transfer company, Yissum. The patent application refers to the novel proprietary composition of Clearmind's MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide ("PEA"), the active ingredient of SciSparc's proprietary CannAmide™, for treating metabolic syndrome and obesity. According to the 2017-2020 data from the National Health and Nutrition examination Survey (NHANES) database, the Centers for Disease Control and Prevention (CDC) reported that among adults aged 20 and over, the prevalence of obesity was 41.9%. According to Emergen Research, the global obesity treatment market size was valued at $15 billion in 2022 and is expected to register a rapid revenue CAGR of 10.0% during the forecast period of 2023 to 2032. Rising prevalence of obesity and technological advancements in weight loss equipment are key factors driving market revenue growth. Overall, as part of the collaboration with SciSparc, twelve other patent applications have been filed by Clearmind with the USPTO for various proprietary compositions, including the composition of SciSparc's PEA with Clearmind's MEAI compounds for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders. Annuncio • May 11
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product Clearmind Medicine Inc. announced advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company has completed most of the pre-clinical studies required for a novel-food application submission according to novel foods and food additives legislation and regulations accepted in many jurisdictions worldwide. Clearmind’s alcohol substitute was granted patents in the U.S., India and Europe. This project is being led by former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, serving as an Executive Special Advisor to the Company. Annuncio • Apr 10
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders Clearmind Medicine Inc. announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide. Annuncio • Mar 27
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression Clearmind Medicine Inc. announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression. This application was previously filed as provisional patent application with the United States Patent and Trademark Office (“USPTO”). According to the ResearchAndMarkets.com, the global depression and anxiety disorders treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034. Overall, as part of this collaboration, nine other patent applications have been filed by Clearmind with the USPTO for various compositions, including the composition of SciSparc’s PEA with Clearmind’s MEAI compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders. Annuncio • Mar 15
Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange Clearmind Medicine Inc. announced that it has applied and received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange ("CSE"). The delisting from the CSE will not affect the company's listing on the NASDAQ Capital Market (the "NASDAQ"). The common shares will continue to trade on the NASDAQ under the symbol CMND. The company believes that the trading volume of its shares on the CSE no longer justifies the expenses and administrative efforts required to maintain a dual listing. The company also believes that delisting from the CSE will create a central marketplace for its common shares on the NASDAQ, and ultimately benefit the long-term liquidity and shareholder value of the company. It is anticipated that, effective as at the close of trading on March 14, 2024, Clearmind’s common shares will no longer be listed and posted for trading on the CSE. Following delisting from the CSE, Clearmind’s shareholders can trade their common shares through their brokers on NASDAQ. Annuncio • Mar 14
Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial Clearmind Medicine Inc. announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule. The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial. The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States for the phase I/IIa clinical trial, at the Yale School of Medicine’s Department of Psychiatry and the Johns Hopkins University School of Medicine. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary endpoint is to evaluate the preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD. Oral capsules will be administered and subjects treated by these oral capsules will report their drinking patterns and cravings for alcohol during the clinical trial. The active ingredient in CMND-100 is MEAI, an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience. MEAI was found to interact with the serotonergic receptors 5-HT1a and 5-HT2a. The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence. MEAI was also found to interact with the alpha-2-adrenergic receptors a2A, a2B and a2C, as well as the plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). These receptors and transporters are believed to participate in mediating alcohol drinking behavior and could constitute important molecular targets for interventions that target drugs subject to abuse, such as alcohol. Annuncio • Feb 23
Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder Clearmind Medicine Inc. announced it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsules. The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States for the phase I/IIa clinical trials, at theale School of Medicine's Department of Psychiatry and the Johns Hopkins University School of Medicine. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in Healthy subjects and those with AUD. The secondary endpoint is to evaluate preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD. Oral capsules will be administered and subjects treated by these oral capsules will report their drinking patterns and cravings for alcohol during the clinical trial. The active ingredient in CMND-100 is MEAI, an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience. MEAI was found to interact with the serotonergic receptors 5-HT1a and 5-HT2a. The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence. MEAI was also found to interact with the alpha-2-adrenergic receptors a2A, a2B and a2C, as well as the plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). These receptors and transporters are believed to participate in mediating alcohol drinking behavior and could constitute important molecular targets for interventions that target drugs subject to abuse, such as alcohol. Annuncio • Feb 06
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration Clearmind Medicine Inc. announced that it has been granted divisional patent approval by the China National Intellectual Property Administration. The granting of this latest patent establishes both the company's patent protection around its molecule as well as its extensive IP protection in the psychedelic space. Clearmind's IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted patents in major jurisdictions such as the US, Europe, China, and India. MEAI is a new psychoactive molecule that reduces desire to consume alcoholic beverages and exerts a slight euphoric, alcohol-like experience with potential to change the lives of millions who struggle to drink in moderation. Clearmind's MEAI-based treatment focuses on Alcohol Use Disorder, which is incredibly common. It varies from mild to excessive and is characterized by a person's inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Clearmind'sMEAI may also be used to treat binge drinking, which can be a deadly addiction for some. Annuncio • Jan 17
Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million. Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 1,500,000
Price\Range: CAD 1.6
Discount Per Security: CAD 0.128
Security Name: Pre-funded Warrants
Security Type: Equity Warrant
Securities Offered: 1,500,000
Transaction Features: Registered Direct Offering Annuncio • Dec 15
Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards Clearmind Medicine Inc. announced that on December 12, 2023 it received a formal notification from The Nasdaq Stock Market LLC ('Nasdaq') that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires the Company's common shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's common shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed. As a result, the scheduled hearing before the Nasdaq Listing Qualifications Hearings Panel requested by the Company to stay the suspension of the Company’s securities from Nasdaq was canceled. The Company is now in compliance with all applicable listing standards and its common shares will continue to be listed and traded on Nasdaq. Annuncio • Dec 03
Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial SciSparc Ltd. announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem. The trial was conducted as part of the collaboration between SciSparc and Clearmind Medicine Inc. a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide™, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression (the “Combination Treatment”). The goal of the trial was to identify the optimal dosage for the Combination Treatment and, in turn, observe the safety and impact thereof on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created (for a total of 84 animals) receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a meaningful degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the Combination Treatment, with the most prominent effects observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated: The administered treatment exhibited a meaningful degree of tolerance, leaving the viability of the mice unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn. A notable reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity. Annuncio • Nov 29
Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment Clearmind Medicine Inc. announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem. The treatment used in the trial combined Clearmind's MEAI, a novel proprietary psychedelic treatment for various addiction, obesity and metabolic disorders and depression, and SciSparc's Palmitoylethanolamide (PEA), which is an anti-inflammatory agent and the active ingredient of its proprietary CannAmide™?. The goal of the trial was to identify the optimal dosage for their combination, to observe their safety and impact on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created (for a total of 84 animals) receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a remarkable degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the combination of MEAI and PEA with the most prominent effects being observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated that: The administered treatment exhibited a remarkable degree of tolerance., leaving the mice' viability unaffected across all experimental group. Combining MEAI and PEA, especially at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. oxygen consumption and carbon dioxide emission indicates increase in metabolic process and fat burn. A striking reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted, particularly at 20 and 10 u/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity. Annuncio • Nov 18
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice Clearmind Medicine Inc. announced receipt of a Staff Delisting Determination (the "Staff Determination") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq"). The Company was notified that Nasdaq has determined to delist the Company's securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share for thirty consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). The Company plans to appeal the Staff’s determination to a Hearings Panel (the “Panel”). A hearing request will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. As part of the plan to regain compliance with the Minimum Bid Price Rule, the Company intends to conduct a reverse stock split as soon as reasonably practicable, subject to applicable law and Nasdaq rules. On November 14th, the Company’s shareholders approved a reverse stock split, which the Company expects will be made effective imminently. Additional details regarding the reverse stock split will be announced in the coming days. “The Company’s shareholders have already approved a reverse stock split, which is expected within the next few weeks, as part of our plan to regain compliance with the Minimum Bid Price Rule,” said Clearmind’s Chief Executive Officer Dr. Adi Zuloff-Shani. “We are looking forward to updating our shareholders regarding the Company’s compliance with the Minimum Bid Price Rule soon”. Annuncio • Nov 10
Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities Clearmind Medicine Inc. announced that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. Clearmind's flagship treatment is focused on AUD, which is an extremely common and devastating condition. The addiction varies from mild to acute and describes a person's inability to control their alcohol consumption, despite negative health, social and occupational consequences. In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period. Patients will also be monitored for their depression symptoms.Johns Hopkins University School of Medicine is the second US-based medical site to join the Company's clinical trial. The first US-based site was Yale School of Medicine'sDepartment of Psychiatry. The potential of psychedelic drugs to treat various neuropsychiatric indications is currently being explored in multiple human clinical trials. In Clearmind's phase I/IIa trial, CM-CMND-001, the primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary endpoint is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and cravings, in individuals with moderate-to-severe AUD. Depression symptoms will also be evaluated as an exploratory endpoint. Annuncio • Oct 10
Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding Clearmind Medicine Inc. announced a private placement to issue 7,500,000 common shares and 7,500,000 pre-funded warrants for the gross proceeds of $2,250,000 on October 9, 2023. These common warrants are immediately exercisable with an exercise price of $0.30 per common share, valid for five years from the issuance date. The transaction is subject to general shareholders of 8th Annual Dawson James Conference which is about to be held on October 12, 2023. Annuncio • Aug 24
Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023 Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023. Annuncio • Aug 02
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S SciSparc Ltd. announced that as part of its ongoing collaboration with Clearmind Medicine Inc. a patent application for the treatment of dyskinesia was filed by Clearmind, a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems. The provisional patent application was filed with the United States Patent and Trademark Office. This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.yskinesia is a category of movement disorders that are characterized by abnormal involuntary movements and may manifest as chorea (ir regular, involuntary movements of the body, especially the face and extremities) or dystonia (disorder or lack of muscle tonicity). Rapid, non-rhythmic, abnormal movements can appear in a host of commonly co-occurring conditions, including Tourette Syndrome and transient tic disorder, as well as during withdrawal from alcohol and other substances. This patent prospect corresponds well with SciSparc's robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome. Annuncio • Jul 12
Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board Clearmind Medicine Inc. announced the appointment of Dr. Fatima Cody Stanford, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, to its Scientific Advisory Board. Dr. Stanford brings extensive expertise in the treatment of obesity, making her a valuable addition to Clearmind’s mission of transforming the treatment landscape for obesity by advancing MEAI as a potential treatment. Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker. Her extensive academic background includes a Bachelor of Science and Master of Public Health from Emory University, a MD from the Medical College of Georgia School of Medicine, a Masters of Public Administration from the Harvard Kennedy School of Government and a MBA from the Quantic School of Business and Technology. Dr. Stanford completed her Obesity Medicine & Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School, further enhancing her expertise in the field. With a career dedicated to bridging the gaps between medicine, public health, and policy, Dr. Stanford has become a sought-after expert in obesity medicine, both nationally and internationally. Her unique perspective and multidisciplinary approach are aligned with Clearmind Medicine’s vision to develop innovative treatments for addiction and address the underlying causes, including obesity. Annuncio • May 24
Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder Clearmind Medicine Inc. announced the selection of its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD"). Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial. The site will be led by Anahita Bassir Nia, MD, a specialist in substance abuse, including alcohol abuse. She joined the Yale School of Medicine in 2018 as an Assistant Professor of Psychiatry, after completing her psychiatry residency at Mount Sinai Beth Israel and her addiction psychiatry fellowship at Mount Sinai West’s Icahn School of Medicine in New York. Clearmind recently announced it had been granted approval by the Ethics Committee (equivalent of an institutional review board) of Israel’s IMCA center for the Phase I/IIa clinical trial of CMND-100. The CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period. The primary end-point of the trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and in those with AUD. The secondary end-point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in individuals with moderate-to-severe AUD. Annuncio • May 22
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification On May 19, 2023, Clearmind Medicine Inc. announced that it has received a written notice (the ‘Notice’) from the Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a grace period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice does not immediately affect the Company's Nasdaq listing or the trading of its ordinary shares. During the grace period, as may be extended, the Company's ordinary shares will continue to trade on Nasdaq under the symbol ‘CMND’. According to the Notice, the Company has until November 13, 2023, to regain compliance with the minimum bid price requirement. The company can regain compliance if, at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum of ten consecutive business days, in which case the Company will be provided with written confirmation of compliance and this matter will be closed. In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting. Annuncio • May 13
Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder Clearmind Medicine Inc. has received Ethics Committee approval for its CM- CMND-001 Phase I/II clinical trial of its MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD") at Israel's IMCA center. CM-CMND-001 is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic Study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat GanThe company intends to have two additional sites in the United States, for this study, subject to signing an agreement with local sites. The primary end point of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those withAUD. The secondary end point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving, in individuals with moderate-to-severe AUD. Oral capsules will be administered once daily, for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.The Ethics Committee (which is the European and Israeli equivalent of the Institutional Review Board (IRB)), of the IMCA center, operating under the Declaration of Helsinki regulations and other international conventions concerning medical experiments on humans, is designated to authorize, review and monitor medical research and trials involving human subjects. The committee reviews research protocols and related materials (such as informed consent documents and investigator brochures) to ensure protection of the rights and welfare of the participants. Annuncio • May 09
Clearmind Medicine Inc. Announces Board Appointments Clearmind Medicine Inc. has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem. Prof. Tam is also a member of the Harvey M. Krueger Family Center for Nanoscience and Nanotechnology, served as president of the International Cannabinoid Research Society, and was a postdoctoral fellow at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the NIH. Annuncio • Feb 16
Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office Clearmind Medicine Inc. announced that it has filed three provisional patent applications with the United States Patent and Trademark Office as part of its ongoing collaboration with pharmaceutical company SciSparc Ltd. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine and SciSparc's Palmitoylethanolamide, the active ingredient of its proprietary CannAmide. SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. These new patent applications demonstrate Clearmind’s corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders waiting for transformative medicines by developing treatments that potentially may offer synergy, increased efficacy, and safety while reducing cost. Clearmind has a broad IP footprint in the psychedelic space with 23 patents in seven patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India. The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders. Annuncio • Feb 01
Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound Clearmind Medicine Inc. announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial (the “trial") resulted in positive outcomes in relation to treating Major Depressive Disorder (“MDD”). The trial evaluated 2-Fluorodeschloroketamine’s (“2-FDCK”), an innovative analogue of Ketamine, of which the Company has a pending patent with the United States Patent and Trademark Office, for its use in treating depression including treatment resistant depression. The purpose of this trial was to determine 2-FDCK's effect on the motivational state of rodents as a treatment for depressive behavior and to test 2-FDCK as a potential novel long-term pharmacological psychoactive treatment for MDD. In the trial, the Flinders Sensitive Line (“FSL”) rat, an animal model of depression, were treated either by Ketamine or 2-FDCK for 14 consecutive days. The results indicated high potential safely treating both acute and chronic depression, compared to Ketamine that is used now for treating depression. The results suggest that there is a superior effect of 2-FDCK vs. Ketamine on the depressive-like behavior of the FSL animal model: Both Ketamine and 2-FDCK affected depressive-like symptoms. However, the effect was longer lasting when using a chronic treatment paradigm, only for 2-FDCK. Annuncio • Jan 18
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment SciSparc Ltd. announced additional positive pre-clinical results in ongoing series of research studies of treatment for cocaine using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY). The results are in connection with the ongoing collaboration between the Company and Clearmind and the provisional patent application for treating cocaine addiction with Clearmind, based on SciSparc’s CannAmide™’s active ingredient Palmitoylethanolamide and Clearmind’s MEAI. The patent application was submitted to the United States Patent and Trademark Office in June 2022. The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel. As previously announced on August 24, 2022, Clearmind's proprietary MEAI at a dose of 5mg/kg, may be effective in the treatment of cocaine addiction by decreased craving for cocaine. The latest research studies were designed to evaluate the effects of MEAI on natural reward, as reward-based positive reinforcement is a shared evolutionary survival strategy across species. However, in drug addiction, reward seeking becomes maladaptive and endangers survival. The purpose of this in-vivo study was to conclude whether MEAI uses the same mechanisms that underlie the seeking of both drug and natural rewards (such as sucrose). The results demonstrated that natural reward was maintained in the MEAI-treated rats, thus showing that the effect of MEAI on drug-seeking is not related to the general reward system. Annuncio • Jan 12
Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial Clearmind Medicine Inc. announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD). The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. Annuncio • Jan 10
Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder Clearmind Medicine Inc. has announced the first agreement to conduct its first- in-human clinical trial using its MEAI-based CMND-100 compound aimed at treating alcohol use disorder. The agreement was signed with the Phase I/II unit at the IMCA center in Ramat Gan, Israel. The trial will be led by Prof. Mark Weiser, head of the Psychiatric Division at the Sheba Medical Center, whose specializations include cognitive impairment in persons with psychiatric disorders such as substance abuse, depression and personality disorders. Annuncio • Jan 06
Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial Clearmind Medicine Inc. announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at the Hebrew University of Jerusalem, as part of a collaboration established with the university’s technology transfer company, Yissum, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI. The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed. Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group. Furthermore, a significant reduction in sucrose preference was observed following administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods. Annuncio • Dec 15
Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100 Clearmind Medicine Inc. announced that it has completed IND-enabling studies on its CMND-100 (MEAI- based) compound aimed at treating alcohol use disorder (AUD), in preparation for its first in-human clinical trial. An Investigational New Drug (IND) application is required by the U.S. Food and Drug Administration (FDA) before commencing clinical studies in humans may initiate. The company is in the process of preparing the IND for its submission to the FDA and the Israeli Ministry of Health. As part of this year-long process, the company preformed pharmacology, pharmacokinetics, and toxicology assessments on the MEAI-based compound. Previous pre-clinical studies using MEAI demonstrated a high safety profile and indications of a significant dose-dependent effect reducing alcohol consumption in treated animals. CMND-100, which is Clearmind’s lead compound, is a novel psychedelic-derived drug candidate, exhibiting compelling evidence that suggests a significant reduction of desire to consume alcoholic beverages- addressing a global unmet need. AUD is a chronic relapsing brain disorder characterized by impaired ability to control alcohol use despite negative social, occupational, and health consequences. One of the world’s gravest health problems, AUD costs the United States alone an estimated $250 billion each year, and is the third leading preventable cause of death in the country. CMND-100 is assumed to suppress the decision to consume more alcohol by potentially innervating neural pathways associated with the 5-HT1A receptor that lead to “sensible behavior.” Clearmind’s intellectual property portfolio includes issued patents in the United States, Europe, China and India covering, among other, the use of CMND-100 in treating AUD. Annuncio • Nov 24
Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial Clearmind Medicine Inc. announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100. The produced batches will be used in the Company's upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD). Following MEAI's synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company's pre- clinical studies designed to evaluate the safety of its innovative compound. The Company previously announce that it completed a highly constructive Pre-Investigational New Drug Application ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the development of CMND-100. Annuncio • Nov 16
Clearmind Medicine Inc. Common Shares Deleted from OTC Equity Clearmind Medicine Inc. Common Shares has been deleted from OTC Equity effective from November 15, 2022, due to Market Center Change Listed on NASDAQ. Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Chairman Amitay Weiss is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Oct 29
Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022 Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022. Annuncio • Aug 25
Clearmind Medicine Announces Additional Positive Pre-Clinical Results for Its Cocaine Addiction Treatment Clearmind Medicine Inc. announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed according to the self-administration paradigm, which is the gold-standard model for examining drug addiction and is based on operant conditioning. In the present trial, animals were catheterized and trained to self-administer cocaine. After the establishment of the addiction model, rats underwent an extinction phase where no cocaine was administered and MEAI was given to the test group. Finally, a relapse phase was carried out where the addicted rats were reminded of the drug with a single administration and then the animals were returned to the self-administration habitat, without receiving the drug. The assumption is that the more an animal yearns to receive the drug, the more it will press on the active pedal. The results identified a sub-group within the study, in a non-biased manner and with high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine, as compared to non-treated control group. This sub-group, representing 60% of animals, showed very high response, within the group and across the board. This pattern of results aligns with a previous Clearmind study which tested the conditioned place-preference paradigm, where similar sub-population group was identified in the context of cocaine preference. This research demonstrates again MEAI’s unique ability to treat cocaine addiction and its potential to become the first dedicated cocaine addiction treatment. Annuncio • Jun 22
Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory Board Clearmind Medicine Inc. announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale University’s School of Medicine. A leading expert on alcoholism, post-traumatic stress disorder, schizophrenia, and depression, Dr. Krystal’s work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine. Dr. Krystal is a Professor of Translational Research; Psychiatry, Neuroscience, and Psychology; he chairs the Department of Psychiatry at Yale University; and he is Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago and the Yale University School of Medicine. Among many other positions he holds or has held, Dr. Krystal is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD, co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; and editor of Biological Psychiatry (IF=12.1). He is a member of the U.S. National Academy of Medicine and a Fellow of the American Association for the Advancement of Science. Annuncio • Jun 17
Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as Director Clearmind Medicine Inc. announced that Mr. Oded Gilboa left his role as a director of the company. Annuncio • Jun 16
Clearmind Medicine Inc. Announces CFO Changes Clearmind Medicine Inc. announced the appointment of Mr. Alan Rootenberg as Chief Financial Officer, effective June 14, 2022 replacing Mr. Oded Gilboa as CFO. Annuncio • Jun 08
Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment Clearmind Medicine Inc. announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference model. Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive. The 5 mg/kg dose was found the most effective dose and selected for further study. The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction. Annuncio • May 26
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment Clearmind Medicine Inc. announced positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. The trial evaluated the proprietary combination of Clearmind's proprietary psychedelic molecule MEAI and SciSparc's CannAmide™ for treating alcohol consumption. Earlier trials successfully showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption in mice, with an additional significant effect achieved when combining CannAmide™ with a lower sub-effective MEAI dose. These positive results follow previously announced results showing that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and higher (p<0.01) compared to consumption before treatment. A histopathology assessment was conducted to determine safety of the proprietary combination of MEAI and CannAmide vs. control (mice that were not exposed to alcohol). Several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) were harvested from all experiment groups (n=3-5 per group) and evaluated for impairment. The severity of impairments was scored by a 5-point scale by a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). Results indicated a high safety profile of the combination treatment with no treatment-related changes observed. Annuncio • May 20
Clearmind Medicine Inc. Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption Clearmind Medicine Inc. announced positive safety results of its proprietary molecule, MEAI, to treat alcohol abuse. To evaluate the efficacy and safety of its psychedelic-derived treatment, Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks. The groups were then given varying daily doses of the new treatment, with intermittent access to alcohol and water. After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving the treatment. The control group showed no statistical significant reduction. Annuncio • May 12
SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors SciSparc Ltd. announced that its recently launched collaboration with Clearmind Medicine Inc. resulted in the filing of a provisional patent application related to a psychedelic combination therapy treating numerous binge behaviors. The patent application refers to the combination of SciSparc's CannAmide™ with Clearmind's MEAI, an innovative proprietary psychedelic treatment for addictions. The patent application followed successful pre-clinical studies that showed a significant dose dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide™ treatment at the lower sub-effective MEAI dose. Initial results of the pre-clinical animal study showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p<0.01) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg and compared to consumption before treatment. The mice were provided with 20% alcohol solution, for 24 hours, three times a week, for seven weeks, and were treated every day with MEAI or MEAI/CannAmide™ during the last two weeks of alcohol treatment. The alcohol consumption was measured by weighing the alcohol bottles before and after; water consumption was measured similarly in parallel. Annuncio • May 10
Clearmind Medicine Inc. Announces the Appointment of Two New Members to Its Scientific Advisory Board Clearmind Medicine Inc. announced the appointment of two new members to its Scientific Advisory Board (“SAB”). Prof. Christian G. Schütz MD PhD MPH FRCPC, of the University of British Columbia, Canada and Prof. Mark Weiser, MD, Chairman of Dept of Psychiatry at Sackler School of Medicine, and head of the Psychiatric Division at Sheba Medical- Center, Israel. Prof. Schütz, an Associate Professor at the Department of Psychiatry in the university’s Faculty of Medicine, focuses on clinical interventions and health service in substance use disorders and dual diagnoses (mental and substance use disorders), as well as neurobiological and neurocognitive aspects of impulsive decision-making. His main research focuses on understanding mechanisms of relapse and impulsive decision-making to improve treatment of addiction and concurrent disorders. He has published over 100 research articles and a dozen chapters. Prof. Weiser, head of the Psychiatric Division at Sheba Medical Hospital, specializes, among others, in cognitive impairment in persons with psychiatric disorders such as substance abuse, depression and personality disorders. Board Change • Apr 27
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Amitay Weiss is the most experienced director on the board, commencing their role in 2019. Independent Director Yehonatan Shachar was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Annuncio • Feb 09
Clearmind Medicine Inc. announced that it expects to receive CAD 0.96 million in funding from Medigus Ltd. Clearmind Medicine Inc. announced a private placement of 1,987,344 units at a subscription price of CAD 0.80 per unit for gross proceeds of CAD 1,589,875 on February 8, 2022. The transaction will include participation from Medigus Ltd. Each unit is comprised of one common share of the company and one common share purchase warrant exercisable into one additional common share at a price per common share of CAD 2, exercisable for a period of 18 months from issuance. Of the gross proceeds, approximately CAD 960,000 will be paid for in cash and approximately CAD 640,000 of the gross proceeds will be satisfied through the issuance to the company of that number of American Depository Shares of Medigus Ltd. arrived at by dividing the share exchange proceeds by $1.20. Annuncio • Jul 01
Clearmind Medicine Inc. announced that it has received CAD 6.225 million in funding On June 30, 2021, Clearmind Medicine Inc. closed the transaction. Each Warrant being exercisable to acquire one additional common share of the company at an exercise price of CAD 1.25 per Warrant Share until December 30,2022. All securities issued are subject to a statutory hold period,expiring onOctober 31, 2021, in accordance with applicable securities legislation. The Company paid finder's fees in association with this financing, payable in cash, of up to 10% of the Gross Proceeds. Annuncio • May 28
Clearmind Medicine Inc. announced that it expects to receive CAD 6 million in funding Clearmind Medicine Inc. (CNSX:CMND) announced a non-brokered private placement of a minimum of 5,000,000 units and a maximum of 8,000,000 units at a price of CAD 0.75 per unit for gross proceeds of minimum CAD 3,750,000 up to a maximum gross proceeds of CAD 6,000,000 on May 27, 2021. Each unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase a common share at a price of CAD 1.25 per warrant for a period of 18 months from the closing. The transaction may include participation from insiders of the company in an amount equal to 20%. The securities issued will be subject to hold period of four months and one day from issuance. The company expects to pay finder's fee payable in cash, of up to 10% of the gross proceeds or alternatively combination of cash in an amount of 5% of gross proceeds and finder warrants equal to 5% of units sold. Each finder warrants will be exercisable into common share at an exercise price of CAD 1 per share for a period of 18 months following the closing of the transaction. The transaction is expected to close on or about June 15, 2021. 